Physician profile
Regina Schmidt
NPI 1013956044
$5,838.63
in general payments reported to CMS, 2019-2025
26 companies · $1,984 in 2025
The $1,984 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $437 · 2022: $1,166 · 2023: $1,018 · 2024: $1,234 · 2025: $1,984.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,235.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,074.89 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $848.36 | 2021-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $682.84 | 2022-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $381.60 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Phathom Pharmaceuticals, INC. | $222.97 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $192.43 | 2024-2025 | Zenpep |
| Pfizer INC. | $151.33 | 2023-2025 | |
| Lilly USA, LLC | $122.75 | 2024-2025 | Omvoh |
| Qol Medical, LLC | $107.38 | 2021-2023 | Sucraid |
| Gilead Sciences, INC. | $103.62 | 2021-2025 | |
| Ardelyx, INC. | $103.28 | 2025 | Ibsrela |
| Braintree Laboratories, INC. | $95.91 | 2021-2024 | Suflave, Sutab |
| Organon LLC | $91.51 | 2023-2025 | Hadlima, Renflexis |
| Regeneron Healthcare Solutions, INC. | $84.69 | 2022-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $83.70 | 2022-2023 | Linzess |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $78.78 | 2022-2024 | Rebyota |
| Vivus LLC | $77.17 | 2021-2023 | Qsymia |
| Ipsen Biopharmaceuticals, INC | $66.71 | 2025 | Iqirvo |
| Celgene Corporation | $61.49 | 2022-2023 | Zeposia |
| Genzyme Corporation | $58.49 | 2023 | |
| Mallinckrodt Hospital Products INC. | $35.93 | 2023 | Terlivaz |
| Intercept Pharmaceuticals, INC. | $29.51 | 2022 | |
| Janssen Scientific Affairs, LLC | $26.07 | 2022 | |
| Madrigal Pharmaceuticals | $24.91 | 2024 | Resmetirom |
| Nestle Healthcare Nutrition INC. | $16.57 | 2022 | |
| Merck Sharp & Dohme LLC | $15.74 | 2023 | Dificid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Regina Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.